MX2020000244A - Vectores virales recombinantes con tropismo modificado y usos de estos para la introduccion dirigida de material genetico a celulas humanas. - Google Patents
Vectores virales recombinantes con tropismo modificado y usos de estos para la introduccion dirigida de material genetico a celulas humanas.Info
- Publication number
- MX2020000244A MX2020000244A MX2020000244A MX2020000244A MX2020000244A MX 2020000244 A MX2020000244 A MX 2020000244A MX 2020000244 A MX2020000244 A MX 2020000244A MX 2020000244 A MX2020000244 A MX 2020000244A MX 2020000244 A MX2020000244 A MX 2020000244A
- Authority
- MX
- Mexico
- Prior art keywords
- recombinant viral
- tropism
- viral vectors
- human cells
- genetic material
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title abstract 2
- 210000005260 human cell Anatomy 0.000 title 1
- 239000013603 viral vector Substances 0.000 title 1
- 108090000565 Capsid Proteins Proteins 0.000 abstract 2
- 102100023321 Ceruloplasmin Human genes 0.000 abstract 2
- 210000000234 capsid Anatomy 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/41—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a Myc-tag
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14145—Special targeting system for viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2810/00—Vectors comprising a targeting moiety
- C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
Abstract
En la presente descripción se proporcionan composiciones y métodos para redireccionar proteínas de la cápside viral/cápsides/vectores recombinantes, por ejemplo in vivo, con una molécula de unión multiespecífica, tal como un anticuerpo biespecífico, que se une específicamente a un epítopo heterólogo presentado por la proteína de la cápside y una proteína expresada en la célula de interés para el suministro dirigido de un nucleótido de interés.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762525704P | 2017-06-27 | 2017-06-27 | |
PCT/US2018/039874 WO2019006043A1 (en) | 2017-06-27 | 2018-06-27 | RECOMBINANT VIRAL VECTORS WITH MODIFIED TROPISM AND USES THEREOF FOR TARGETED INTRODUCTION OF GENETIC MATERIAL INTO HUMAN CELLS |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020000244A true MX2020000244A (es) | 2020-09-28 |
Family
ID=63080487
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020000244A MX2020000244A (es) | 2017-06-27 | 2018-06-27 | Vectores virales recombinantes con tropismo modificado y usos de estos para la introduccion dirigida de material genetico a celulas humanas. |
MX2023009050A MX2023009050A (es) | 2017-06-27 | 2020-01-08 | Vectores virales recombinantes con tropismo modificado y usos de estos para la introduccion dirigida de material genetico a celulas humanas. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2023009050A MX2023009050A (es) | 2017-06-27 | 2020-01-08 | Vectores virales recombinantes con tropismo modificado y usos de estos para la introduccion dirigida de material genetico a celulas humanas. |
Country Status (19)
Country | Link |
---|---|
US (1) | US20200140491A1 (es) |
EP (1) | EP3645551B1 (es) |
JP (3) | JP7372154B2 (es) |
KR (1) | KR20200022434A (es) |
CN (2) | CN117051045A (es) |
AU (2) | AU2018290882B2 (es) |
BR (2) | BR112019027854A2 (es) |
CA (1) | CA3066947A1 (es) |
CL (2) | CL2019003842A1 (es) |
CO (1) | CO2019014683A2 (es) |
DK (1) | DK3645551T3 (es) |
FI (1) | FI3645551T3 (es) |
IL (1) | IL271573A (es) |
MA (1) | MA49513A (es) |
MX (2) | MX2020000244A (es) |
PE (1) | PE20200488A1 (es) |
PH (1) | PH12019550266A1 (es) |
SG (1) | SG11201911610TA (es) |
WO (1) | WO2019006043A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3736330A1 (en) * | 2019-05-08 | 2020-11-11 | European Molecular Biology Laboratory | Modified adeno-associated virus (aav) particles for gene therapy |
EP3976631A1 (en) | 2019-05-24 | 2022-04-06 | Regeneron Pharmaceuticals, Inc. | Modified viral particles and uses thereof |
WO2021230987A1 (en) | 2020-05-13 | 2021-11-18 | Voyager Therapeutics, Inc. | Redirection of tropism of aav capsids |
JP2023548432A (ja) | 2020-11-11 | 2023-11-16 | ヨーロピアン モレキュラー バイオロジー ラボラトリー | 遺伝子療法のための改変ウイルス粒子 |
CA3233698A1 (en) | 2021-11-04 | 2023-05-11 | Regeneron Pharmaceuticals, Inc. | Viral particles retargeted to skeletal muscle |
CN114213505B (zh) * | 2021-12-10 | 2022-09-20 | 和元生物技术(上海)股份有限公司 | 一种适用于特异感染u87-mg细胞的腺相关病毒突变体 |
WO2023164448A1 (en) * | 2022-02-22 | 2023-08-31 | The University Of North Carolina At Chapel Hill | Chimeric neurotropic aav capsids |
WO2023220603A1 (en) * | 2022-05-09 | 2023-11-16 | Regeneron Pharmaceuticals, Inc. | Vectors and methods for in vivo antibody production |
WO2023215947A1 (en) * | 2022-05-13 | 2023-11-16 | Children's Medical Research Institute | Adeno-associated virus capsids |
WO2024026494A1 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Viral particles retargeted to transferrin receptor 1 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0840797B1 (en) | 1995-07-25 | 2014-09-03 | Crucell Holland B.V. | Methods and means for targeted gene delivery |
EP1053013A4 (en) | 1998-02-06 | 2004-12-22 | Uab Research Foundation | ADENOVIRUS VECTOR CONTAINING A HETEROLOGICAL PEPTIDEPITOP IN THE HI LOOP OF THE FIBER BUTTON |
DE19849643A1 (de) * | 1998-10-29 | 2000-05-04 | Deutsches Krebsforsch | An das AAV-Kapsid bindender, den Zelltropismus verändernder Antikörper und Verfahren zum gerichteten Gentransfer |
DE19933719A1 (de) * | 1999-07-19 | 2001-01-25 | Medigene Ag | Strukturprotein in Adeno-assoziiertem Virus mit veränderten chromatographischen Eigenschaften, seine Herstellung und Verwendung |
WO2004025259A2 (en) * | 2002-09-12 | 2004-03-25 | Molecular Probes, Inc. | Site-specific labeling of affinity tags in fusion proteins |
US7273835B2 (en) * | 2004-08-04 | 2007-09-25 | Honeywell International Inc. | Azeotrope-like compositions of difluoromethane |
CA2605024C (en) | 2005-04-15 | 2018-05-22 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
US9963510B2 (en) | 2005-04-15 | 2018-05-08 | Macrogenics, Inc. | Covalent diabodies and uses thereof |
EP2012122A1 (en) * | 2007-07-06 | 2009-01-07 | Medigene AG | Mutated parvovirus structural proteins as vaccines |
US20100203083A1 (en) | 2007-05-31 | 2010-08-12 | Medigene Ag | Mutated structural protein of a parvovirus |
PL2975051T3 (pl) | 2009-06-26 | 2021-09-20 | Regeneron Pharmaceuticals, Inc. | Wyizolowane z łatwością dwuswoiste przeciwciała o formacie natywnej immunoglobuliny |
LT2954779T (lt) | 2009-12-10 | 2019-05-27 | Regeneron Pharmaceuticals, Inc. | Pelės, gaminančios sunkiosios grandinės antikūnus |
WO2014022540A1 (en) | 2012-08-02 | 2014-02-06 | Regeneron Pharmaceuticals, Inc. | Multivalent antigen-binding proteins |
CA2917018A1 (en) * | 2013-05-21 | 2014-12-04 | University Of Florida Research Foundation, Inc. | Capsid-modified, raav3 vector compositions and methods of use in gene therapy of human liver cancer |
KR20210088756A (ko) | 2014-03-21 | 2021-07-14 | 리제너론 파마슈티칼스 인코포레이티드 | 단일 도메인 결합 단백질을 생산하는 비-인간 동물 |
WO2016054554A1 (en) * | 2014-10-03 | 2016-04-07 | University Of Massachusetts | Heterologous targeting peptide grafted aavs |
-
2018
- 2018-06-27 JP JP2019572024A patent/JP7372154B2/ja active Active
- 2018-06-27 CN CN202310920054.9A patent/CN117051045A/zh active Pending
- 2018-06-27 KR KR1020207001282A patent/KR20200022434A/ko not_active Application Discontinuation
- 2018-06-27 MA MA049513A patent/MA49513A/fr unknown
- 2018-06-27 BR BR112019027854-0A patent/BR112019027854A2/pt unknown
- 2018-06-27 PE PE2019002652A patent/PE20200488A1/es unknown
- 2018-06-27 US US16/625,189 patent/US20200140491A1/en active Pending
- 2018-06-27 CA CA3066947A patent/CA3066947A1/en active Pending
- 2018-06-27 SG SG11201911610TA patent/SG11201911610TA/en unknown
- 2018-06-27 EP EP18749635.1A patent/EP3645551B1/en active Active
- 2018-06-27 WO PCT/US2018/039874 patent/WO2019006043A1/en unknown
- 2018-06-27 CN CN201880042990.1A patent/CN110799524A/zh active Pending
- 2018-06-27 MX MX2020000244A patent/MX2020000244A/es unknown
- 2018-06-27 AU AU2018290882A patent/AU2018290882B2/en active Active
- 2018-06-27 BR BR122023021213-4A patent/BR122023021213A2/pt unknown
- 2018-06-27 DK DK18749635.1T patent/DK3645551T3/da active
- 2018-06-27 FI FIEP18749635.1T patent/FI3645551T3/fi active
-
2019
- 2019-12-05 PH PH12019550266A patent/PH12019550266A1/en unknown
- 2019-12-19 IL IL271573A patent/IL271573A/en unknown
- 2019-12-24 CO CONC2019/0014683A patent/CO2019014683A2/es unknown
- 2019-12-26 CL CL2019003842A patent/CL2019003842A1/es unknown
-
2020
- 2020-01-08 MX MX2023009050A patent/MX2023009050A/es unknown
- 2020-12-22 CL CL2020003343A patent/CL2020003343A1/es unknown
-
2022
- 2022-10-11 JP JP2022163041A patent/JP2022183228A/ja active Pending
-
2023
- 2023-07-19 AU AU2023206143A patent/AU2023206143A1/en active Pending
-
2024
- 2024-02-08 JP JP2024017826A patent/JP2024036644A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
RU2020101279A (ru) | 2021-07-27 |
MA49513A (fr) | 2020-05-06 |
BR122023021213A2 (pt) | 2024-02-20 |
PH12019550266A1 (en) | 2021-01-11 |
FI3645551T3 (fi) | 2024-05-03 |
CN110799524A (zh) | 2020-02-14 |
SG11201911610TA (en) | 2020-01-30 |
EP3645551A1 (en) | 2020-05-06 |
JP7372154B2 (ja) | 2023-10-31 |
PE20200488A1 (es) | 2020-03-03 |
CL2019003842A1 (es) | 2020-07-24 |
CA3066947A1 (en) | 2019-01-03 |
WO2019006043A1 (en) | 2019-01-03 |
MX2023009050A (es) | 2023-08-10 |
CN117051045A (zh) | 2023-11-14 |
CL2020003343A1 (es) | 2021-06-25 |
JP2022183228A (ja) | 2022-12-08 |
US20200140491A1 (en) | 2020-05-07 |
CO2019014683A2 (es) | 2020-01-17 |
EP3645551B1 (en) | 2024-03-13 |
AU2018290882B2 (en) | 2023-07-27 |
JP2020529196A (ja) | 2020-10-08 |
AU2018290882A1 (en) | 2020-01-16 |
JP2024036644A (ja) | 2024-03-15 |
BR112019027854A2 (pt) | 2020-07-07 |
RU2020101279A3 (es) | 2022-02-04 |
IL271573A (en) | 2020-02-27 |
KR20200022434A (ko) | 2020-03-03 |
DK3645551T3 (da) | 2024-05-06 |
AU2023206143A1 (en) | 2023-08-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2023009050A (es) | Vectores virales recombinantes con tropismo modificado y usos de estos para la introduccion dirigida de material genetico a celulas humanas. | |
EA201991911A1 (ru) | Способы и композиции для переноса генов по сосудистой сети | |
MX2020001198A (es) | Agentes de union que se unen a ligando 1 de muerte programada (pd-l1) y grupo de diferenciacion 137 (cd137) y uso de los mismos. | |
MX2018010824A (es) | Proteinas de union inducibles y metodos de uso. | |
WO2017058892A3 (en) | Methods and compositions for antibody-evading virus vectors | |
WO2012159006A8 (en) | Polypeptides and vectors for targeting her2/neu expressing cells and uses thereof | |
IL259120A (en) | Her2-targeted antigen chimeric receptors2 | |
JOP20200313A1 (ar) | أجسام مضادة dll3-cd3 ثنائية الخاصية | |
MX2023009051A (es) | Particulas virales recombinantes con tropismo modificado y usos de estas para la introduccion orientada de material genetico en celulas humanas. | |
PH12020551039A1 (en) | Non-viral dna vectors and uses thereof for antibody and fusion protein production | |
EA202090956A3 (ru) | Антитела к cd73 и их применения | |
SG195181A1 (en) | Simian adenovirus and hybrid adenoviral vectors | |
EP4249036A3 (en) | Methods and products for nucleic acid production and delivery | |
PH12020551907A1 (en) | Antagonizing cd73 antibody | |
PH12014501988A1 (en) | Pharmaceutical formulations of tnf-alpha antibodies | |
EP4269560A3 (en) | Modified epidermal growth factor receptor peptides for use in genetically-modified cells | |
JP2017538401A5 (es) | ||
MX2022009674A (es) | Seleccion directa de celulas que expresan niveles altos de proteinas heterodimericas usando vectores de complementacion intragenica de glutamina sintetasa. | |
MX2020002921A (es) | Anticuerpos para claudin6 y métodos para tratar el cáncer. | |
WO2013119371A3 (en) | Mini-intronic plasmid vectors | |
AU2024201649A1 (en) | A fully-human T cell receptor specific for the 369-377 epitope derived from the HER2/Neu (ERBB2) receptor protein | |
JP2019514399A5 (es) | ||
WO2016130628A8 (en) | Griffithsin mutants | |
CR20210094A (es) | ANTICUERPOS QUE SE UNEN A LA PROTEÍNA DE ENVOLTURA DEL VIRUS ZIKA Y USOS DE LOS MISMOS (Divisional 2019-0193) | |
AU2018276376A1 (en) | Cell culture methods |